Jun 6, 2024, 04:19
Roy Herbst shared the updated results from the COAST clinical trial – Yale Cancer Center
Yale Cancer Center shared a post on X:
“Roy Herbst shared the updated results from the COAST clinical trial, a phase 2 study of durvalumab with/without oleclumab or monalizumab in patients with stage 3 unresectable NSCLC.”
Source: Yale Cancer Center/X
Jul 27, 2024, 11:24